Vifor Drops CV Endpoints In Phase IIIb Veltassa Study After COVID-19 Impacts

Vifor Pharma is still hoping for further clinical data to help differentiate its potassium binder Veltassa in the competitive hyperkalemia market after recruitment into its Phase IIIb DIAMOND study was slowed by COVID-19-related changes to clinical practice, necessitating a new primary endpoint.